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ABSTRACT _
This paper reviews various published reports from sur-
veys on employer opinion, perception of needs, and
trends with regard to healthcare benefits; the consumer
perspective regarding healthcare is also discussed. Sur-
veys indicate that businesses want continuous evidence
that high-quality healthcare can positively impact com-
pany profits. Employers and labor unions are demanding
more cost-effective healthcare. At both employer and
consumer levels, greater patient education is needed, as
well as traditional educational media. Direct-to-con-
sumer advertising and use of the World Wide Web are
increasingly important in enabling consumers to partici-
pate more fully in their own lipid-related decision-making.
Finally, the transition of lipid-lowering drugs to over-the-
Various national surveys have been conductedconcerning employer opinion and perception
of needs with regard to healthcare services, insur-
ance benefits, and the high cost of coronary heart
disease. Several reports have appeared in a periodi-
cal produced by Medical Economics called Business
& Health, which has a circulation of about 50,000
employers, benefit managers and medical directors
throughout the United States. Over the last year
and a half Business & Health has published a series
called "Costing Out Care," which reviews the cost-
effectiveness of various disease treatments and drug
classes, including lipid therapy [1]. The consumer
perspective on coronary heart disease (CHD) will
also be discussed in this article; direct-to-consumer
advertising and use of the World Wide Web (WWW)
are of growing significance and are enabling con-
sumers to playa far more important role in health
decisions. Finally, the transition of lipid-lowering
drugs to over-the-counter accessibility has implica-
tions for employers and consumers, including cho-
lesterol self-testing and lipid self-treatment.
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counter accessibility has great implications with respect
to issues of patient preferences and willingness to pay in
the evolving healthcare environment. Groups in the
United States, such as the National Committee on Qual-
ity Assurance and the Foundation for Accountability, are
setting standards and beginning to assess both process
and outcomes in patient care. Further collaborative ef-
forts are needed that raise standards of care and stimu-
late more cost-effective healthcare. The pharmacoeco-
nomics and outcomes data gathered will, one hopes, also
demonstrate to global businesses the positive financial
impact of high-quality healthcare and appropriate lipid
therapy.
The Employer Perspective
What are employers' attitudes with regard to
healthcare in general? Robert Cole, a director of
the Washington Business Group on Health, reports
that companies are looking for healthcare that pro-
duces a better bottom line. This includes products
and services that reduce disability and absenteeism
and improve morale and productivity [2]. From
the perspective of business, these expected benefits
should accrue within a period of 2-10 years (Fig. 1).
Most consumers and patients can be expected to
have a long-term perspective extending to 70 years
or more. In today's employment environment there
rarely exists lifetime employment; employee turn-
over rates in the United States are high. When mak-
ing decisions about lipids and cholesterol, the em-
ployer may only be taking into account a 2-10-year
window. Hopefully, within this time frame, they
will be able to realize some of the benefits obtain-
able from lipid therapy.
The managed care perspective is somewhat dif-
ferent; an average patient is said to stay in anyone
managed care plan from 1 to 3 years. Obviously,
this time frame will be an issue in examining lipid-
lowering agents and cholesterol reduction. From
the for-profit point of view, stockholders want a
company to show an increase in productivity and
profits over a financial quarter, or the year. From
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Figure I The time perspective in health interventions.
these short-term perspectives it may be difficult to
support long-term therapy for preventing cardio-
vascular disease. In evaluating lipid-lowering ther-
apy protocols, employers want to know whether
they will save money in the first quarter, over the
first year of therapy, and in each year afterwards.
This is the information they want documented, not
just in clinical trials but also, ideally, in their own
employee populations.
A 1997 survey by Business & Health of 438 em-
ployers asked about their general concerns on health-
care issues (Fig. 2) [3]. On a five-point scale, with 5
indicating "very concerned" and 1 indicating "not
at all concerned," the monetary cost of health bene-
fits was considered most important, followed
closely by the quality of healthcare provided. Cost-
effective decision-making on the part of employees
(i.e., self-care and risk-aversive behavior) was also
important, followed closely by employee satisfac-
tion with a managed care organization (MCO), the
cost of prescriptions, and regulations affectingMCOs,
such as length-of-stay mandates. When questioned
about the rising costs of prescription drugs, 41 % of
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employers were "very concerned," but they were
more concerned about overall benefit costs.
In the same survey [3], when asked about the
importance of certain factors in selecting a health
plan (on a 100-point scale where 100 indicates very
important), employers most valued low premium
rates, with the patient's choice of primary care phy-
sician following closely (Fig. 3). With scores just
over 10 each, access to specialists, performance to
recognized quality standards, and plan accredita-
tion, were considered much less important.
In another survey [4], of all employers ques-
tioned, 28% in 1996 and 33% in 1997 generally
agreed that cost controls and cost containment
have a negative effect on quality of care. There was
variation in response according to company size,
with smaller firms (fewer than 1000 employees) in-
dicating a greater degree of agreement with this
concept (45% agreeing in small firms versus 24%
in larger firms in 1997). This represents an increase
from 1996, when only 33% of smaller firms and
23 % of larger firms agreed with the concept.
In a 1997 study performed by the Pharmacy
Benefit Management Institute [5], when asked how
they rated pharmacy benefit managers (PBMs), em-
ployers expressed dissatisfaction. When all ratings
of 5 or less on a Tfl-point scale were combined,
41 % of employers surveyed were not satisfied with
the ability of PBMs to deliver as promised in dis-
ease management. About 30% of employers were
dissatisfiedwith the PBM management reports, prom-
ised savings, retrospective drug utilization reviews
(DUR), and formulary management. Between 18%
and 25% expressed a lack of satisfaction with the
use of concurrent DUR, the cost of drugs, mail or-
der services, and generic substitutions.
Regulation of MCOs
Prescription Costs
Employee
Satisfaction
Cost-effective
Employees
Quality of Care
Health Benefit Cost
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Figure 2 Companies' concerns about
some healthcare issues (N = 438; I = not
at all concerned; 5 = very concerned).
Adapted from [3]. MCa. managed care
organization.
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Figure 3 Companies' scoring importance
when selecting a health plan (N = 438;
I = not at all important; I00 = very im-
portant). Adapted from [3].
Very unlikely
Figure 4 Employers planning to require integration of pre-
scription and medical data. Adapted from [6].
How Do Employers Evaluate
Healthcare Plans?
Although there is concern by some about its em-
phasis on employer perspective, the US National
Committee on Quality Assurance (NCQA) Health
Plan Employer Data and Information Set (HEDIS)
should at least raise awareness of the potential bene-
fits of lipid monitoring in healthcare plans. HEDIS
is a set of standardized performance measures de-
signed to ensure that employers and consumers have
information needed to compare the performance of
healthcare plans [7]. Some HEDIS results have al-
ready been published on the WWW for review by
consumers and employers (www.ncqa.org). With
these standard-setting efforts, in one 1997 NCQA
report on 228 HMOs with about 28 million me.m-
bers, cholesterol screening was reported as bemg
done 68% of the time. It should be noted however,
that HEDIS uses process measures and not necessar-
William Mercer has conducted a national survey
[6] to evaluate what new initiatives employers are
planning in prescription drug management. When
all "very likely" and "somewhat likely" responses
are combined, two items, 1) building more inte-
grated disease state management programs an~ 2)
using prescription drugs to reduce overall medical
costs, account for approximately 80% of employer
positive responses in this survey. Almost 70% of re-
spondents suggested that they intended to make
more aggressive use of formularies to control drugs,
and perhaps costs.
In the William Mercer survey [6], employers
were asked whether they had plans to require inte-
gration by their PBMs of prescription drug and
medical data (Fig. 4). Most of the employers who
responded to this survey emphasized the impor-
tance of integration. The "silo effect," or indepen-
dence of budgets for drug, laboratory, medical, and
hospitalization costs, is recognized as a significant
problem. Seventy percent of employers believed
that "required integration" was "very likely" or
"somewhat likely."
The partnering of employers with pharmaceutical
companies was also explored by William Mercer [6].
Twenty-one percent of employer groups thought it
very likely that they might collaborate with pharma-
ceutical companies, while 37% responded that they
were somewhat likely; 39% thought collaboration
unlikely. However, only 7% of employers thought it
likely that they would contract directly with phar-
maceutical firms, 17% thought it somewhat likely,
and 75% felt it unlikely. So, while collaboration
was considered more likely, direct contracting was
not something in which most employers seemed
interested.
Very likely
Undecided
21"1.
Somewhat
likely
Somewhat
unlikely
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ily outcome measures (process measures include, for
instance, flu shots given for high-risk adults, aspirin
treatment after heart attack, controlling high blood
pressure, quitting smoking, and cholesterol manage-
ment of patients hospitalized for coronary artery
disease). From HEDIS data, we cannot learn actual
patient average LDL levels, response to treatment
with various agents, or patient compliance with
treatment. However, monitoring the process of care
can be a beneficial beginning. Both employers and
labor unions are working with NCQA to analyze
general healthcare services. We need to improve
data collection in order to more comprehensively
evaluate health plans and compare outcomes and
costs.
The US Foundation for Accountability (FACCT)
differs from the NCQA in that its mission is to in-
volve more consumer groups along with employers
and the healthcare industry (healthcare providers
and health insurance) [8]. FACCT sponsors re-
search on a range of issues that affect consumers
and plans to canvass groups of consumers and
purchasers through focus groups, reactor panels,
surveys, and general forums. FACCT wants to
represent a larger consumer/patient perspective and
intends to evaluate actual health-system outcome
measures. Some of the FACCT measurement sets
are similar to those of HEDIS. They have not yet
listed target measurements specific to lipids or cho-
lesterol but do indicate an intention to evaluate cor-
onary artery disease, coronary risk factor reduc-
tion, diabetes, and hypertension.
It is doubtful that many HMOs are currently
providing employers with feedback that includes
information about lipid levels in their populations.
The Interstudy Competitive Edge [9] reported that,
while cost and resource utilization data are most
frequently provided to employers, and patient-sat-
isfaction data are fairly routine (almost 90% of
HMOs), few HMOs provide disease incidence in-
formation (just over 40%) or information regard-
ing health status or mortality rates (around 20%).
Approximately 70% of HMOs said they provide
employers with HEDIS or other report cards, but
no details were provided about what type of infor-
mation is included in these reports.
Challenges to employers about cost-effective
cholesterol healthcare coverage have been pub-
lished (see [1]) to stimulate thought and action in
decision-making on health benefits. These include
the following questions: Are the US National Cho-
lesterol Education Program guidelines implemented
in employers' benefit plans? Are educational materi-
als provided to employees? Is cost-effectiveness con-
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.sidered in formulary decision-making and therapeutic
priority-setting? Are individual patient preferences
and quality-of-life considerations incorporated into
treatment protocols? Are dietary consultations and
self-administered blood cholesterol testing kits pro-
vided for employees?
Raising the Priority of Lipid Therapy
Tengs et al. have published an extensive table in
Risk Analysis Journal, in which lipid-lowering agents
demonstrated significantly better cost-effectiveness
(CE) ratios in terms of life-years saved than many
other life-saving interventions [10]. While there are
many difficulties associated with the use of cost-
effectiveness tables for comparative purposes, they
are useful for emphasizing to employers and/or to
health plans the concept of relative priority, and for
demonstrating that lipid-lowering agents should be
accorded greater importance. Employers are cur-
rently paying for many things that are not highly
cost-effective compared to lipid therapy; in some
cases they are even required by law to do so (e.g.,
asbestos control, benzene control). The business
community (employers) needs to realign priorities
and pay more attention to the cost-effective use of
lipid therapies.
The Oregon Medicaid ranking system is an ex-
ample of how to set priorities in healthcare, al-
though they do not appear to clearly have included
cholesterol reduction in their early rankings. Ore-
gon attempted to rationalize decision-making in
times of limited resources, and, as a result, created
an interesting approach to cost-effectiveness, rank-
ing services, making comparisons, and setting prior-
ities. This might be one model to help employers
and health insurance programs evaluate importance
and to work through coverage priorities. Items
ranked as high priority for Medicaid coverage in-
cluded vaccinations and antibiotic therapy, while in-
terventions where there is little hope that the patient
would recover, such as severe head injury or multio-
rgan failure, were ranked at lowest priority. (See
http://ohppr.das.state.or.us/pubslliscsum.htm)
Educating the Employer and the Consumer
How can employers and patients be better educated
about health interventions? One obvious key lies in
the distribution of educational materials. There are
already numerous patient education materials in
the field of lipids and cholesterol. A listing of some
of this material was published in Business &
Health [1], and there is a great deal available on the
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Figure 5 Percent of healthcare consum-
ers rating each source "very believable,"
Adapted from [12].
World Wide Web. There are many good materials
that we can encourage employers and health plans
to distribute.
The American Heart Association's website (www.
amhrt.org) has an interactive risk appraisal algo-
rithm that provides a viewer with immediate person-
alized risk feedback (http://www.amhrt.orglHAW/
calccvd.htm). There is no doubt that this will
evolve to include information about how to deal
with those risks (i.e., diet modification, smoking
cessation, cholesterol and lipid-lowering strategies),
as well as interactive programs that demonstrate
how each of these changes affects risk level. The
WWW is and will continue to be a valuable tool for
consumer education.
The appropriateness of direct-to-consumer ad-
vertising is an ongoing debate. Well-constructed
and fair advertising is another medium for educat-
ing consumers about the benefits and cost-effective-
ness of lipid-lowering therapy.
If lipid drugs move to over-the-counter (OTC)
status, and if more is paid out of the individual's
pocket and not just by health plans, lipid-lowering
therapy may become more of a willingness-to-pay
issue. Cholesterol blood test kits are already avail-
able OTe. To appreciate how much consumers will
pay to extend or protect their lives, one can exam-
ine the value of life calculated from the purchase
price of smoke detectors. From their initial intro-
duction on the market, the price of detectors dropped
from about $150 per device to $24, as recognition
of their value grew and more people purchased
them. It is estimated that the early purchasers of
smoke detectors valued life at about $2 million. As
more detectors were sold, the calculated marginal
value of life dropped to about $350,000 per life
saved [11]. This is calculated on the real risk of
death and is a prevention issue: you don't buy a
smoke detector once the fire starts in your house. I
believe that we often underestimate how much pa-
tients really value their lives and their willingness to
pay, even out of pocket. Although willingness to
pay is certainly affected by patients ability to pay, if
we research these concepts more fully, we should be
able to achieve better patient compliance and greater
patient willingness to use therapies for healthier cho-
lesterollevels.
If we are educating consumers about the cost-
effectiveness of lipid therapy and attempting to
modify behavior, it is important that consumers
perceive the sources of this material to be credible.
A Kaiser Family Foundation and Agency for Health
Care Policy and Research survey looked at the "be-
lievability" of various sources of healthcare con-
sumer information (Fig. 5) [12]. As can be seen, the
media does not fare very well, and the WWW is not
included in the survey and so cannot be evaluated.
Family and friends are most believable, with about
50% of consumers finding them a credible source,
followed by patient surveys (just over 30%) and in-
dividual physicians (just under 30%).
Conclusions
Employers are interested in comprehensive health
packages. Businesses and employers need to be
able to see that high-quality healthcare has a posi-
tive impact on their bottom lines. Employers and
labor unions want healthcare that is more cost-
effective. Organizations such as the NCQA and
FACCT, by setting standards and assessing actual
outcomes, can provide the basis for evaluating and
comparing healthcare plans. All this will, it is
hoped, stimulate provision of more cost-effective
healthcare, with room for variation based on indi-
vidual patient preferences.
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To this end, consumers, employers, and benefit
managers will need to be better educated about the
costs and benefits of lipid therapy. Through health
professionals and the World Wide Web, and by di-
rect-to-consumer communications, more effective
education must take place. Finally, the issues of pa-
tient preferences, quality of life, and willingness to
pay must be examined more closely if evolving
healthcare interventions are to optimize cardiovas-
cular health.
The author thanks Richard Service and Helen Lippman of
Business & Health for supplying some of the surveyinfor-
mation used in this article. This article was prepared with
the assistance of BioMedComConsultants inc., Montreal,
Canada.
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